Zurück zur Übersicht
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 Jun 3. pii: mdv257. doi: 10.1093/annonc/mdv257. pmc: PMC4511225 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. |
| Gillessen S1, Omlin A2, Attard G3, de Bono JS4, Efstathiou E5, Fizazi K6, Halabi S7, Nelson PS8, Sartor O9, Smith MR10, Soule HR11, Akaza H12, Beer TM13, Beltran H14, Chinnaiyan AM15, Daugaard G16, Davis ID17, De Santis M18, Drake CG19, Eeles RA20, Fanti S21, Gleave ME22, Heidenreich A23, Hussain M24, James ND25, Lecouvet FE26, Logothetis CJ27, Mastris K28, Nilsson S29, Oh WK30, Olmos D31, Padhani AR32, Parker C33, Rubin MA34, Schalken JA35, Scher HI36, Sella A37, Shore ND38, Small EJ39, Sternberg CN40, Suzuki H41, Sweeney CJ42, Tannock IF43, Tombal B44 |
 Author information
|
|
Abstract The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged. |
|
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. |
|
KEYWORDS: advanced prostate cancer, castration-naïve prostate cancer, castration-resistant prostate cancer, consensus, therapeutics |
|
Publikations ID: 26041764 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
